CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 398 enrolled
Drug / intervention
LY2484595 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01105975
NCT01105975Phase 2Completed

A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C

Eli Lilly and Company·interventional·Posted Apr 19, 2010·Updated Mar 22, 2018

In Brief

A Phase 2 clinical trial evaluating LY2484595, Atorvastatin, and 4 other interventions for Dyslipidemia. Completed, enrolled 398 participants across 59 sites in 6 countries.

Detailed Summary

The primary purpose of your participation in this study is to help answer the following research question(s) * Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile more than statins alone. * Whether LY2484595 alone improves blood fats profile compared to sugar pills. * Whether LY2484595 interferes with break down or functioning of statins. * Whether LY2484595 has any side effects that would not support testing it in future studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesDenmark, Germany, Netherlands, Poland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2010
Enrollment StartApr 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.2 years ago

Interventions

LY2484595drug

Administered daily by mouth for 12 weeks

Atorvastatindrug

Administered daily by mouth for 12 weeks

Simvastatindrug

Administered daily by mouth for 12 weeks

Rosuvastatindrug

Administered daily by mouth for 12 weeks

Placebo for LY2484595drug

Administered daily by mouth for 12 weeks

Placebo for Statinsdrug

Administered daily by mouth for 12 weeks